114 related articles for article (PubMed ID: 25943068)
21. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Larkin J; Chiarion-Sileni V; Gonzalez R; Grob JJ; Cowey CL; Lao CD; Schadendorf D; Dummer R; Smylie M; Rutkowski P; Ferrucci PF; Hill A; Wagstaff J; Carlino MS; Haanen JB; Maio M; Marquez-Rodas I; McArthur GA; Ascierto PA; Long GV; Callahan MK; Postow MA; Grossmann K; Sznol M; Dreno B; Bastholt L; Yang A; Rollin LM; Horak C; Hodi FS; Wolchok JD
N Engl J Med; 2015 Jul; 373(1):23-34. PubMed ID: 26027431
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.
Heskamp S; Hobo W; Molkenboer-Kuenen JD; Olive D; Oyen WJ; Dolstra H; Boerman OC
Cancer Res; 2015 Jul; 75(14):2928-36. PubMed ID: 25977331
[TBL] [Abstract][Full Text] [Related]
23. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.
Kwek SS; Lewis J; Zhang L; Weinberg V; Greaney SK; Harzstark AL; Lin AM; Ryan CJ; Small EJ; Fong L
Cancer Immunol Res; 2015 Sep; 3(9):1008-16. PubMed ID: 25968455
[TBL] [Abstract][Full Text] [Related]
24. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
26. Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.
Xia Y; Jeffrey Medeiros L; Young KH
Biochim Biophys Acta; 2016 Jan; 1865(1):58-71. PubMed ID: 26432723
[TBL] [Abstract][Full Text] [Related]
27. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
Siravegna G; Mussolin B; Buscarino M; Corti G; Cassingena A; Crisafulli G; Ponzetti A; Cremolini C; Amatu A; Lauricella C; Lamba S; Hobor S; Avallone A; Valtorta E; Rospo G; Medico E; Motta V; Antoniotti C; Tatangelo F; Bellosillo B; Veronese S; Budillon A; Montagut C; Racca P; Marsoni S; Falcone A; Corcoran RB; Di Nicolantonio F; Loupakis F; Siena S; Sartore-Bianchi A; Bardelli A
Nat Med; 2015 Jul; 21(7):795-801. PubMed ID: 26030179
[TBL] [Abstract][Full Text] [Related]
28. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
Van Allen EM; Golay HG; Liu Y; Koyama S; Wong K; Taylor-Weiner A; Giannakis M; Harden M; Rojas-Rudilla V; Chevalier A; Thai T; Lydon C; Mach S; Avila AG; Wong JA; Rabin AR; Helmkamp J; Sholl L; Carter SL; Oxnard G; Janne P; Getz G; Lindeman N; Hammerman PS; Garraway LA; Hodi FS; Rodig SJ; Dranoff G; Wong KK; Barbie DA
Cancer Immunol Res; 2015 Aug; 3(8):855-63. PubMed ID: 26014096
[TBL] [Abstract][Full Text] [Related]
29. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Callea M; Albiges L; Gupta M; Cheng SC; Genega EM; Fay AP; Song J; Carvo I; Bhatt RS; Atkins MB; Hodi FS; Choueiri TK; McDermott DF; Freeman GJ; Signoretti S
Cancer Immunol Res; 2015 Oct; 3(10):1158-64. PubMed ID: 26014095
[TBL] [Abstract][Full Text] [Related]
30. Regulatory B cells in anti-tumor immunity.
Zhang Y; Gallastegui N; Rosenblatt JD
Int Immunol; 2015 Oct; 27(10):521-30. PubMed ID: 25999597
[TBL] [Abstract][Full Text] [Related]
31. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.
Nastoupil LJ; Neelapu SS
Curr Oncol Rep; 2015 Jul; 17(7):30. PubMed ID: 25986722
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint modulation for non-small cell lung cancer.
Soria JC; Marabelle A; Brahmer JR; Gettinger S
Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
[TBL] [Abstract][Full Text] [Related]
33. Classifying Cancers Based on T-cell Infiltration and PD-L1.
Teng MW; Ngiow SF; Ribas A; Smyth MJ
Cancer Res; 2015 Jun; 75(11):2139-45. PubMed ID: 25977340
[TBL] [Abstract][Full Text] [Related]
34. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.
Bracarda S; Altavilla A; Hamzaj A; Sisani M; Marrocolo F; Del Buono S; Danielli R
Semin Oncol; 2015 Jun; 42(3):495-505. PubMed ID: 25965369
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.
Baksh K; Weber J
Semin Oncol; 2015 Jun; 42(3):363-77. PubMed ID: 25965355
[TBL] [Abstract][Full Text] [Related]
36. Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy.
Kim YJ
Oncoimmunology; 2014 Dec; 3(12):e954868. PubMed ID: 25964860
[TBL] [Abstract][Full Text] [Related]
37. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Liu J; Yuan Y; Chen W; Putra J; Suriawinata AA; Schenk AD; Miller HE; Guleria I; Barth RJ; Huang YH; Wang L
Proc Natl Acad Sci U S A; 2015 May; 112(21):6682-7. PubMed ID: 25964334
[TBL] [Abstract][Full Text] [Related]
38. IFNγ producing CD8
Buferne M; Chasson L; Grange M; Mas A; Arnoux F; Bertuzzi M; Naquet P; Leserman L; Schmitt-Verhulst AM; Auphan-Anezin N
Oncoimmunology; 2015 Feb; 4(2):e974959. PubMed ID: 25949872
[TBL] [Abstract][Full Text] [Related]
39. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
Salles G; Barrett M; Foà R; Maurer J; O'Brien S; Valente N; Wenger M; Maloney DG
Adv Ther; 2017 Oct; 34(10):2232-2273. PubMed ID: 28983798
[TBL] [Abstract][Full Text] [Related]
40. Progression and Transformation of Clonally Heterogeneous B-cell Lymphoma.
Weiss RF; Smith MR; Miller MG; Cronin JF
PLoS One; 2015; 10(6):e0130590. PubMed ID: 26068800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
